This study will examine the pharmacokinetic profile and safety of the O'Neil Long Acting
Naltrexone Implant (OLANI) overtime in healthy volunteers. All participants will be treated
in an open label manner. No randomization will occur. It is hypothesized that the OLANI will
provide sustained therapeutic doses of naltrexone (NTX) for periods up to 6 months via a
single subcutaneous application of 2 OLANIs.
Phase:
Phase 1
Details
Lead Sponsor:
Go Medical Industries Pty Ltd
Collaborators:
Clinilabs, Inc. Columbia University National Institute on Drug Abuse (NIDA) New York State Psychiatric Institute